Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

11/12/24 10:40:28 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $XLO alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.3 XILIO THERAPEUTICS INC COMMON STOCK Cusip #98422T100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #98422T100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,395,853 Item 6: 0 Item 7: 1,395,853 Item 8: 0 Item 9: 1,395,853 Item 11: 3.175% Item 12: HC Cusip #98422T100 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 1,395,853 Item 8: 0 Item 9: 1,395,853 Item 11: 3.175% Item 12: IN Item 1(a). Name of Issuer: XILIO THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 828 WINTER STREET WALTHAM, MA 02451 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 98422T100 Item 3. Not Applicable Item 4. Ownership (a) Amount Beneficially Owned: 1,395,853 (b) Percent of Class: 3.175% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 1,395,853 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of XILIO THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of XILIO THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification IMPRESA MANAGEMENT LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of XILIO THERAPEUTICS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $XLO alert in real time by email

Recent Analyst Ratings for

$XLO

Date	Price Target	Rating	Analyst
8/6/2025	$2.00	Outperform	Leerink Partners
12/21/2022	$7.00	Buy	Chardan Capital Markets
1/10/2022	$36.00	Buy	HC Wainwright & Co.
11/16/2021	$40.00	Buy	Guggenheim
11/16/2021	$31.00	Outperform	Raymond James
11/16/2021		Outperform	Cowen & Co.
11/16/2021	$32.00	Overweight	Morgan Stanley

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

11/12/24 10:40:28 AM ET

$XLO

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $XLO alert in real time by email

Recent Analyst Ratings for

$XLO

Date	Price Target	Rating	Analyst
8/6/2025	$2.00	Outperform	Leerink Partners
12/21/2022	$7.00	Buy	Chardan Capital Markets
1/10/2022	$36.00	Buy	HC Wainwright & Co.
11/16/2021	$40.00	Buy	Guggenheim
11/16/2021	$31.00	Outperform	Raymond James
11/16/2021		Outperform	Cowen & Co.
11/16/2021	$32.00	Overweight	Morgan Stanley

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$XLO

Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$XLO

$XLO
Insider Purchases

Director Shannon James Samuel bought $48,085 worth of shares (70,000 units at $0.69) (SEC Form 4)

PRESIDENT AND CEO Russo Rene bought $24,680 worth of shares (36,289 units at $0.68), increasing direct ownership by 15% to 281,172 units (SEC Form 4)

Large owner Gilead Sciences, Inc. bought $1,830,377 worth of shares (1,759,978 units at $1.04), increasing direct ownership by 24% to 9,105,451 units (SEC Form 4)

$XLO
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Xilio Therapeutics Inc.

SEC Form 10-Q filed by Xilio Therapeutics Inc.

Xilio Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$XLO
Press Releases

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$XLO
Insider Trading

Director Shannon James Samuel bought $48,085 worth of shares (70,000 units at $0.69) (SEC Form 4)

PRESIDENT AND CEO Russo Rene bought $24,680 worth of shares (36,289 units at $0.68), increasing direct ownership by 15% to 281,172 units (SEC Form 4)

Amendment: SEC Form 4 filed by PRESIDENT AND CEO Russo Rene

$XLO
Leadership Updates

Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

$XLO
Analyst Ratings

Leerink Partners initiated coverage on Xilio Therapeutics with a new price target

Chardan Capital Markets initiated coverage on Xilio Therapeutics with a new price target

HC Wainwright & Co. initiated coverage on Xilio Therapeutics with a new price target

$XLO
Large Ownership Changes